Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer.

× No keyword cloud information.

29 in total

Review 1. Selegiline and Parkinson's disease. Protective and symptomatic considerations.

Authors: L I Golbe; J W Langston; I Shoulson
Journal: Drugs Date: 1990-05 Impact factor: 9.546

2. R-deprenyl: pharmacological spectrum of its activity.

Authors: K Magyar; B Szende; V Jenei; T Tábi; M Pálfi; E Szöko
Journal: Neurochem Res Date: 2010-08-20 Impact factor: 3.996

Review 3. The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression.

Authors: Eleni Pitsillou; Sarah M Bresnehan; Evan A Kagarakis; Stevano J Wijoyo; Julia Liang; Andrew Hung; Tom C Karagiannis
Journal: Mol Biol Rep Date: 2019-10-14 Impact factor: 2.316

Review 4. Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

Authors: John P M Finberg
Journal: J Neural Transm (Vienna) Date: 2018-11-01 Impact factor: 3.575

Review 5. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).

Authors: I Miklya
Journal: Mol Psychiatry Date: 2016-08-02 Impact factor: 15.992

6. Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment.

Authors: A Prasad; V Glover; B L Goodwin; M Sandler; M Signy; S E Smith
Journal: Psychopharmacology (Berl) Date: 1988 Impact factor: 4.530

7. Effect of nonselective and selective inhibitors of monoamine oxidases A and B on pethidine toxicity in mice.

Authors: R Boden; R Botting; P Coulson; G Spanswick
Journal: Br J Pharmacol Date: 1984-05 Impact factor: 8.739

8. Pharmacokinetic and neurochemical studies on N-propargyl-2-phenylethylamine, a prodrug of 2-phenylethylamine.

Authors: T S Rao; G B Baker; R T Coutts
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1987-07 Impact factor: 3.000

Review 9. Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives.

Authors: Joseph Knoll
Journal: Neurochem Res Date: 2003-08 Impact factor: 3.996

Review 10. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors: P Chrisp; G J Mammen; E M Sorkin
Journal: Drugs Aging Date: 1991-05 Impact factor: 3.923